N-hydroxy-N'-phenyloctanediamide
GPTKB entity
Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:histone_deacetylase_inhibitor |
| gptkbp:alternativeName |
gptkb:SAHA
gptkb:suberoylanilide_hydroxamic_acid |
| gptkbp:ATCCode |
L01XX50
|
| gptkbp:CASNumber |
149647-78-9
|
| gptkbp:hasInChIKey |
LFYFEWAGGLJEEJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C14H20N2O2
|
| gptkbp:hasSMILES |
C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
|
| gptkbp:is_approved_for_treatment_of |
gptkb:leukemia
|
| gptkbp:IUPACName |
gptkb:N-hydroxy-N'-phenyloctanediamide
|
| gptkbp:mechanismOfAction |
inhibits histone deacetylases
|
| gptkbp:meltingPoint |
151-153°C
|
| gptkbp:partOf |
vorinostat (pharmaceutical preparation)
|
| gptkbp:PubChem_CID |
5311
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:usedFor |
anticancer agent
epigenetic drug |
| gptkbp:was_approved_by |
gptkb:FDA
|
| gptkbp:bfsParent |
gptkb:SAHA
gptkb:vorinostat gptkb:Vorinostat |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
N-hydroxy-N'-phenyloctanediamide
|